Role of Toll like receptor in progression and suppression of oral squamous cell carcinoma
Oral squamous cell carcinoma (OSCC) is one of the most common type of head and neck squamous cell carcinoma and one of the multifactorial process that consists of most contributing factors such as tobacco smoking, chewing and alcohol consumption that altered the intracellular environment. Recent studies have shown relevance of Toll like receptor (TLR) associated with carcinogenesis. This review aim’s to explore that how TLR associates with progression and suppression of OSCC. This review is a classical review that has confined to articles published in the past 19 years (i.e. 2000-2019) and has summarized the perspective of the authors. 62 articles were reviewed and it was found that progression and suppression of OSCC is associated with different TLRs promoting tumor development and also inhibiting the progression of oral neoplasm. It was found that TLR2, TLR3, TLR4, TLR5, TLR7 and TLR9 are associated with tumor development i.e. in progression of OSCC, where as suppression of OSCC through TLR3 and TLR7. We authors would like to conclude that literature survey has indicated effective TLR’s against OSCC development and can be explored to investigate other TLRs that can be used for therapeutic purposes in near future.
2. Tezal M, Sullivan MA, Hyland A, Marshall JR, Stoler D, Reid ME, et al. Chronic Periodontitis and the Incidence of Head and Neck Squamous Cell Carcinoma. Cancer Epidemiol Prev Biomarkers [Internet]. 2009;18(9):2406–12. Available from: https://cebp.aacrjournals.org/content/18/9/2406
3. Pisani LP, Estadella D, Ribeiro DA. The Role of Toll Like Receptors (TLRs) in Oral Carcinogenesis. Anticancer Res. 2017 Oct;37(10):5389–94.
4. Fukata M, Chen A, Vamadevan AS, Cohen J, Breglio K, Krishnareddy S, et al. Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology. 2007 Dec;133(6):1869–81.
5. Ruckdeschel K, Pfaffinger G, Haase R, Sing A, Weighardt H, Hacker G, et al. Signaling of apoptosis through TLRs critically involves toll/IL-1 receptor domain-containing adapter inducing IFN-beta, but not MyD88, in bacteria-infected murine macrophages. J Immunol. 2004 Sep;173(5):3320–8.
6. Kauppila JH, Mattila AE, Karttunen TJ, Salo T. Toll-like receptor 5 (TLR5) expression is a novel predictive marker for recurrence and survival in squamous cell carcinoma of the tongue. Br J Cancer. 2013 Feb;108(3):638–43.
7. Chuang H-C, Huang C-C, Chien C-Y, Chuang J-H. Toll-like receptor 3-mediated tumor invasion in head and neck cancer. Oral Oncol. 2012 Mar;48(3):226–32.
8. Takeda K, Akira S. Toll-like receptors in innate immunity. Int Immunol. 2005 Jan;17(1):1–14.
9. Yang Z-H, Dai Q, Gu Y-J, Guo Q-X, Gong L. Cytokine and chemokine modification by Toll-like receptor polymorphisms is associated with nasopharyngeal carcinoma. Cancer Sci. 2012 Apr;103(4):653–8.
10. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J cancer. 2006 Jun;118(12):3030–44.
11. Rich AM, Hussaini HM, Parachuru VPB, Seymour GJ. Toll-like receptors and cancer, particularly oral squamous cell carcinoma. Front Immunol. 2014;5:464.
12. Ridnour LA, Cheng RYS, Switzer CH, Heinecke JL, Ambs S, Glynn S, et al. Molecular pathways: toll-like receptors in the tumor microenvironment--poor prognosis or new therapeutic opportunity. Clin Cancer Res. 2013 Mar;19(6):1340–6.
13. Pradere J-P, Dapito DH, Schwabe RF. The Yin and Yang of Toll-like receptors in cancer. Oncogene. 2014 Jul;33(27):3485–95.
14. Xie W, Wang Y, Huang Y, Yang H, Wang J, Hu Z. Toll-like receptor 2 mediates invasion via activating NF-kappaB in MDA-MB-231 breast cancer cells. Biochem Biophys Res Commun. 2009 Feb;379(4):1027–32.
15. Hua D, Liu M-Y, Cheng Z, Qin X-J, Zhang H-M, Chen Y, et al. Small interfering RNA-directed targeting of Toll-like receptor 4 inhibits human prostate cancer cell invasion, survival, and tumorigenicity. Mol Immunol. 2009 Sep;46(15):2876–84.
16. Killeen SD, Wang JH, Andrews EJ, Redmond HP. Bacterial endotoxin enhances colorectal cancer cell adhesion and invasion through TLR-4 and NF-kappaB-dependent activation of the urokinase plasminogen activator system. Br J Cancer. 2009 May;100(10):1589–602.
17. Lee C-H, Wu C-L, Shiau A-L. Toll-like receptor 4 signaling promotes tumor growth. J Immunother. 2010 Jan;33(1):73–82.
18. Yu L, Wang L, Chen S. Dual character of Toll-like receptor signaling: pro-tumorigenic effects and anti-tumor functions. Biochim Biophys Acta. 2013 Apr;1835(2):144–54.
19. Xie W, Huang Y, Xie W, Guo A, Wu W. Bacteria peptidoglycan promoted breast cancer cell invasiveness and adhesiveness by targeting toll-like receptor 2 in the cancer cells. PLoS One. 2010 May;5(5):e10850.
20. de Camargo Cancela M, Voti L, Guerra-Yi M, Chapuis F, Mazuir M, Curado MP. Oral cavity cancer in developed and in developing countries: population-based incidence. Head Neck. 2010 Mar;32(3):357–67.
21. Shenoi R, Devrukhkar V, Sharma BK, Sapre SB, Chikhale A. Demographic and clinical profile of oral squamous cell carcinoma patients: a retrospective study. Indian J Cancer. 2012;49(1):21–6.
22. Rivera C, Venegas B. Histological and molecular aspects of oral squamous cell carcinoma (Review). Oncol Lett. 2014 Jul;8(1):7–11.
23. Chen Y, Azad MB, Gibson SB. Superoxide is the major reactive oxygen species regulating autophagy. Cell Death Differ. 2009 Jul;16(7):1040–52.
24. Akram S, Mirza T, Aamir Mirza M, Qureshi M. Emerging Patterns in Clinico-pathological spectrum of Oral Cancers. Pakistan J Med Sci. 2013 May;29(3):783–7.
25. Dikshit RP, Kanhere S. Tobacco habits and risk of lung, oropharyngeal and oral cavity cancer: a population-based case-control study in Bhopal, India. Int J Epidemiol. 2000 Aug;29(4):609–14.
26. D’Souza G, Gross ND, Pai SI, Haddad R, Anderson KS, Rajan S, et al. Oral human papillomavirus (HPV) infection in HPV-positive patients with oropharyngeal cancer and their partners. J Clin Oncol. 2014 Aug;32(23):2408–15.
27. Plemons JM, Al-Hashimi I, Marek CL. Managing xerostomia and salivary gland hypofunction: executive summary of a report from the American Dental Association Council on Scientific Affairs. J Am Dent Assoc. 2014 Aug;145(8):867–73.
28. von Bultzingslowen I, Sollecito TP, Fox PC, Daniels T, Jonsson R, Lockhart PB, et al. Salivary dysfunction associated with systemic diseases: systematic review and clinical management recommendations. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007 Mar;103 Suppl:S57.e1-15.
29. Jerjes W, Upile T, Petrie A, Riskalla A, Hamdoon Z, Vourvachis M, et al. Clinicopathological parameters, recurrence, locoregional and distant metastasis in 115 T1-T2 oral squamous cell carcinoma patients. Head Neck Oncol. 2010 Apr;2:9.
30. Ali J, Sabiha B, Jan HU, Haider SA, Khan AA, Ali SS. Genetic etiology of oral cancer. Oral Oncol. 2017 Jul;70:23–8.
31. Shcheblyakov D V, Logunov DY, Tukhvatulin AI, Shmarov MM, Naroditsky BS, Gintsburg AL. Toll-Like Receptors (TLRs): The Role in Tumor Progression. Acta Naturae. 2010 Jul;2(3):21–9.
32. Yu L, Wang L, Chen S. Endogenous toll-like receptor ligands and their biological significance. J Cell Mol Med. 2010 Nov;14(11):2592–603.
33. Yu L, Chen S. Toll-like receptors expressed in tumor cells: targets for therapy. Cancer Immunol Immunother. 2008 Sep;57(9):1271–8.
34. Ng LK, Rich AM, Hussaini HM, Thomson WM, Fisher AL, Horne LS, et al. Toll-like receptor 2 is present in the microenvironment of oral squamous cell carcinoma. Br J Cancer. 2011 Feb;104(3):460–3.
35. Sutmuller R, Garritsen A, Adema GJ. Regulatory T cells and toll-like receptors: regulating the regulators. Ann Rheum Dis. 2007 Nov;66 Suppl 3:iii91-5.
36. Morais CA, de Rosso VV, Estadella D, Pisani LP. Anthocyanins as inflammatory modulators and the role of the gut microbiota. J Nutr Biochem. 2016 Jul;33:1–7.
37. Jouhi L, Koljonen V, Bohling T, Haglund C, Hagstrom J. The expression of Toll-like receptors 2, 4, 5, 7 and 9 in Merkel cell carcinoma. Anticancer Res. 2015 Apr;35(4):1843–9.
38. Kohailan M, Alanazi M, Rouabhia M, Alamri A, Parine NR, Alhadheq A, et al. Effect of smoking on the genetic makeup of toll-like receptors 2 and 6. Onco Targets Ther. 2016;9:7187–98.
39. Ikehata N, Takanashi M, Satomi T, Watanabe M, Hasegawa O, Kono M, et al. Toll-like receptor 2 activation implicated in oral squamous cell carcinoma development. Biochem Biophys Res Commun. 2018 Jan;495(3):2227–34.
40. Luo Q, Hu S, Yan M, Sun Z, Chen W, Chen F. Activation of Toll-like receptor 3 induces apoptosis of oral squamous carcinoma cells in vitro and in vivo. Int J Biochem Cell Biol. 2012 Aug;44(8):1266–75.
41. Zeljic K, Supic G, Jovic N, Kozomara R, Brankovic-Magic M, Obrenovic M, et al. Association of TLR2, TLR3, TLR4 and CD14 genes polymorphisms with oral cancer risk and survival. Oral Dis. 2014 May;20(4):416–24.
42. Omar AAH, Korvala J, Haglund C, Virolainen S, Hayry V, Atula T, et al. Toll-like receptors -4 and -5 in oral and cutaneous squamous cell carcinomas. J oral Pathol Med Off Publ Int Assoc Oral Pathol Am Acad Oral Pathol. 2015 Apr;44(4):258–65.
43. Sun Z, Luo Q, Ye D, Chen W, Chen F. Role of toll-like receptor 4 on the immune escape of human oral squamous cell carcinoma and resistance of cisplatin-induced apoptosis. Mol Cancer. 2012 May;11:33.
44. Kotrashetti VS, Nayak R, Bhat K, Hosmani J, Somannavar P. Immunohistochemical expression of TLR4 and TLR9 in various grades of oral epithelial dysplasia and squamous cell carcinoma, and their roles in tumor progression: a pilot study. Biotech Histochem. 2013 Aug;88(6):311–22.
45. Ren WH, Zhang LM, Liu HQ, Gao L, Chen C, Qiang C, et al. Protein overexpression of CIRP and TLR4 in oral squamous cell carcinoma: an immunohistochemical and clinical correlation analysis. Med Oncol. 2014 Aug;31(8):120.
46. Ruan M, Thorn K, Liu S, Li S, Yang W, Zhang C, et al. The secretion of IL-6 by CpG-ODN-treated cancer cells promotes T-cell immune responses partly through the TLR-9/AP-1 pathway in oral squamous cell carcinoma. Int J Oncol. 2014 Jun;44(6):2103–10.
47. Han S, Xu W, Wang Z, Qi X, Wang Y, Ni Y, et al. Crosstalk between the HIF-1 and Toll-like receptor/nuclear factor-kappaB pathways in the oral squamous cell carcinoma microenvironment. Oncotarget. 2016 Jun;7(25):37773–89.
48. He Z, Deng R, Huang X, Ni Y, Yang X, Wang Z, et al. Lipopolysaccharide enhances OSCC migration by promoting epithelial-mesenchymal transition. J oral Pathol Med Off Publ Int Assoc Oral Pathol Am Acad Oral Pathol. 2015 Oct;44(9):685–92.
49. Grimm M, Munz A, Exarchou A, Polligkeit J, Reinert S. Immunohistochemical detection of Helicobacter pylori without association of TLR5 expression in oral squamous cell carcinoma. J oral Pathol Med Off Publ Int Assoc Oral Pathol Am Acad Oral Pathol. 2014 Jan;43(1):35–44.
50. Sato J, Nishimura M, Yamazaki M, Yoshida K, Kurashige Y, Saitoh M, et al. Expression profile of drosomycin-like defensin in oral epithelium and oral carcinoma cell lines. Arch Oral Biol. 2013 Mar;58(3):279–85.
51. Ni YH, Ding L, Zhang DY, Hou YY, Huang X, Hu Q. Distinct expression patterns of Toll-like receptor 7 in tumour cells and fibroblast-like cells in oral squamous cell carcinoma. Histopathology. 2015 Nov;67(5):730–9.
52. Diakowska D, Nienartowicz M, Grabowski K, Rosinczuk J, Krzystek-Korpacka M. Toll-like receptors TLR-2, TLR-4, TLR-7, and TLR-9 in tumor tissue and serum of the patients with esophageal squamous cell carcinoma and gastro-esophageal junction cancer. Adv Clin Exp Med. 2019 Apr;28(4):515–22.
53. Min R, Siyi L, Wenjun Y, Shengwen L, Ow A, Lizheng W, et al. Toll-like receptor-9 agonists increase cyclin D1 expression partly through activation of activator protein-1 in human oral squamous cell carcinoma cells. Cancer Sci. 2012 Nov;103(11):1938–45.
54. Makinen LK, Atula T, Hayry V, Jouhi L, Datta N, Lehtonen S, et al. Predictive role of Toll-like receptors 2, 4, and 9 in oral tongue squamous cell carcinoma. Oral Oncol. 2015 Jan;51(1):96–102.
55. Mikulandra M, Pavelic J, Glavan TM. Recent Findings on the Application of Toll-like Receptors Agonists in Cancer Therapy. Curr Med Chem. 2017;24(19):2011–32.
56. Jin C, Flavell RA. Innate sensors of pathogen and stress: linking inflammation to obesity. J Allergy Clin Immunol. 2013 Aug;132(2):287–94.
57. Park J-H, Jeon D-I, Yoon H-E, Kwon S-M, Kim S-A, Ahn S-G, et al. Poly I:C inhibits cell proliferation and enhances the growth inhibitory effect of paclitaxel in oral sqaumous cell carcinoma. Acta Odontol Scand. 2012 May;70(3):241–5.
58. Luo W, Wang C-Y, Jin L. Baicalin downregulates Porphyromonas gingivalis lipopolysaccharide-upregulated IL-6 and IL-8 expression in human oral keratinocytes by negative regulation of TLR signaling. PLoS One. 2012;7(12):e51008.
59. He Z, Huang X, Ni Y, Shi P, Wang Z, Han W, et al. Functional toll-like receptor 3 expressed by oral squamous cell carcinoma induced cell apoptosis and decreased migration. Oral Surg Oral Med Oral Pathol Oral Radiol. 2014 Jul;118(1):92–100.
60. Ahn M-Y, Kwon S-M, Cheong HH, Park J-H, Lee J, Min S-K, et al. Toll-like receptor 7 agonist, imiquimod, inhibits oral squamous carcinoma cells through apoptosis and necrosis. J oral Pathol Med Off Publ Int Assoc Oral Pathol Am Acad Oral Pathol. 2012 Aug;41(7):540–6.
- Abstract views: 62
- PDF: 17
- HTML: 0
Copyright (c) 2020 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.